Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

June 2, 2022

FDA Fast Tracks Novel Immunotherapy-Keytruda Combo for HPV-Related Head and Neck Cancer

Author(s):

Brielle Benyon

The Food and Drug Administration granted a fast track designation to PDS0101 plus Keytruda for the treatment of patients with recurrent or metastatic HPV16-related head and neck cancer.

The Food and Drug Administration (FDA) granted a fast track designation to PDS0101 plus Keytruda (pembrolizumab) for the treatment of patients with recurrent or metastatic HPV16-positive head and neck cancer, according to PDS Biotech, the pharmaceutical company manufacturing PDS0101.

The goal of fast track designations, according to the FDA, is to fill unmet medical needs by expediting the review and development of promising drugs. This is the case for head and neck cancer, a disease whose incidence continues to increase in the United States. Research has also shown that the majority of HPV-driven head and neck cancers are driven by the HPV16 strain.

“The HPV-associated head and neck cancer prevalence continues to rise, leaving this affected group with limited treatment options to date. Receiving this designation underscores … the need for a new therapy that may improve outcomes for those with this devastating disease,” Frank Bedu-Addo, CEO of PDS Biotech, said in a press release.

PDS0101 is an HPV-specific immunotherapy that may be able to stimulate high levels of HPV16-specific CD8+ and CD4+ T cells to attack the disease. The drug is delivered via injection under the skin, and prior research has shown that it can potentially target anal, cervical, head and neck, penile, vaginal and vulvar cancers that are related to the HPV 16 infection.

The drug duo is currently being investigated in the open-label phase 2 VERSATILE-002 clinical trial, where all patients will receive both PDS0101 and Keytruda; there is no placebo or control group.

Preliminary data from the first 19 patients enrolled in the trial showed that PDS0101 plus Keytruda led to a 41% response rate in patients with recurrent or metastatic head and neck cancer. Eighty-nine percent of patients were alive at an average of nine months, and 76.5% of patients experienced either disease stabilization or tumor shrinkage. The majority (94%) of patients on the trial received four out of five of the doses, with no severe (grade 3 or higher) side effects.

Data from the VERSATILE-002 clinical trial will be presented at the upcoming ASCO Annual Meeting.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of goy, and text.
Watch oncology dietitian Kenisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.
Image of bald man.
Image of man with black hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Dr. Michael Moore
Related Content
Advertisement
Image of Dr. with text
June 26th 2025

Eating Tips for When Cancer Treatment Makes Meals Challenging

Spencer Feldman
Greek yogurt, egg salad, avocado and mac and cheese are easy-to-swallow, high-calorie foods that can help patients maintain strength during cancer treatment.
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck: © stock.adobe.com.
June 1st 2025

Adjuvant Opdivo Combo Improves Survival Outcomes in Advanced Head and Neck Cancer

Ariana Pelosci
Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck.
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
August 10th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Image of woman holding her neck.
May 5th 2025

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Ryan Scott
First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.
Illustration of neck.
April 25th 2025

Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer

Alex Biese
In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.
Related Content
Advertisement
Image of Dr. with text
June 26th 2025

Eating Tips for When Cancer Treatment Makes Meals Challenging

Spencer Feldman
Greek yogurt, egg salad, avocado and mac and cheese are easy-to-swallow, high-calorie foods that can help patients maintain strength during cancer treatment.
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck: © stock.adobe.com.
June 1st 2025

Adjuvant Opdivo Combo Improves Survival Outcomes in Advanced Head and Neck Cancer

Ariana Pelosci
Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck.
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
August 10th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Image of woman holding her neck.
May 5th 2025

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Ryan Scott
First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.
Illustration of neck.
April 25th 2025

Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer

Alex Biese
In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.